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Abstract Varicose veins without skin changes have a
prevalence of approximately 20% in Northern and Western
Europe whereas advanced chronic venous insufﬁciency
affects about 3% of the population. Genetic risk factors are
thought to play an important role in the aetiology of both
these chronic venous diseases (CVD). We evaluated the
relativegeneticandenvironmentalimpactuponCVDriskby
estimating the heritability of the disease in 4,033 nuclear
families, comprising 16,434 individuals from all over Ger-
many. Upon clinical examination, patients were classiﬁed
according to the CEAP guidelines as either C2 (simple vari-
cose veins), C3 (oedema), C4 (skin changes without ulcer-
ation), C5 (healed ulceration), or C6 (active ulcers). The
narrow-sense heritability (h
2) of CVD equals 17.3% (stan-
darderror2.5%,likelihoodratiotestP = 1.4 9 10
-13).The
proportion of disease risk attributable to age (at ascertain-
ment) and sex, the two main risk factors for CVD, was
estimated as 10.7% (Kullback–Leibler deviance R
2). The
heritability of CVD is high, thereby suggesting a notable
genetic component in the aetiology of the disease. System-
atic population-based searches forCVD susceptibilitygenes
are therefore warranted.
Background
Chronic venous disease (CVD) is one of the most common
disorders in Northern and Western Europe. According to
the CEAP classiﬁcation, CVD comprises those clinical
entities that are characterized by visible venous ecstasies
but which are not associated with an identiﬁable mecha-
nism of venous dysfunction (Porter and Moneta 1995;
Kistner et al. 1996). The clinical presentation of CVD
ranges from complication-free telangiectasias or reticular
veins, via varicose veins (VV) without oedema and skin
changes, to venous ulceration. Varicose veins requiring
medical care but lacking signs of oedema or skin changes
are sometimes referred to as ‘simple VV’ and have been
given CEAP classiﬁcation C2. If skin changes or ulcer-
ations occur, patients are deﬁned as having ‘chronic vein
insufﬁciency’ (CVI), classiﬁed as CEAP C3 to C6 (Ruck-
ley et al. 2002). Deﬁned in this way, CVD represents a
summary term comprising patients with either simple VV
or CVI (Eklof et al. 2004, 2009). Epidemiological studies
of CVD have revealed that VV affects 16–46% of females
and 12–40% of males (Evans et al. 1999; Rabe et al. 2003;
Carpentier et al. 2004). The prevalence of CVI ranges from
5 to 18% in females, and from 7 to 15% in males (Evans
et al. 1999; Rabe et al. 2003; Carpentier et al. 2004).
Although CVD is relatively common, the aetiologic
factors predisposing individuals to the dilatation, elonga-
tion and tortuosity of the saphenous vein and its tributaries
are still poorly understood. The clinically observed thick-
ening of the vessel wall appears to be associated with an
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(Sansilvestri-Morel et al. 2007). In addition to age, sex and
obesity, family history was also found to be a major risk
factor for CVD (Coon et al. 1973; Abramson et al. 1981;
Brand et al. 1988; Franks et al. 1992; Sisto et al. 1995;D e
Backer 1997). However, family data were often inconsis-
tent and confounded by selection bias (Meissner 2004). A
CVD twin study reported 84% phenotypic concordance
between monozygotic twins, compared to only 39%
between dizygotic twins (Niermann 1964). In view of these
ambiguities, we set out to formally assess the heritability of
CVD in a large sample of affected nuclear families from all
over Germany.
Materials and methods
Between October 2005 and July 2008, a total of 2,701
index patients with CVD were recruited at the Capio
Mosel-Eifel-Clinic (Capio MEC, Bad Bertrich, Germany),
which is specialized in the treatment of severe forms of
CVD. The ethics committee of the Kiel medical faculty and
the local data protection authorities both approved the
study. Written informed consent was obtained from all
participants. Exclusion criteria were clinically overt
debility, any signs of acute deep vein thrombosis and
congenital causes of CVD. All patients suffered from
severe injury of their great saphenous vein and had stayed
in the clinic for at least 4 days.
A questionnaire was administered to each index patient
by Capio MEC staff to obtain information on their demo-
graphic and personal characteristics (sex, date and place of
birth, parental origin) as well as their medical history
(medical treatment, pain, severe operations, age at CVD
onset,presenceofdeepveinthrombosis,phlebitis).Duration
of disease (in years) was calculated from these data as the
difference between age at ascertainment and age at onset. A
30-ml blood sample for further genetic analysis, including
candidate gene and genome wide association studies, was
takenbyCapioMECstaffandimmediatelyfrozenat-20C.
Genomic DNA was prepared from defrosted blood samples
using the Invisorb Blood Giga Kit (Invitec, Berlin, Ger-
many). All DNA samples were quality-checked on agarose
gels. Patients were alsointerviewed about the CVD status of
all living ﬁrst degree relatives (parents and siblings). Family
information was provided by all 2,701 index patients, which
generated 4,033 nuclear families comprising 16,434 indi-
viduals for heritability analysis (Table 1).
All index patients were classiﬁed according to the
severity, cause, site and speciﬁc abnormalities of their
disease, using the CEAP classiﬁcation. The CEAP classi-
ﬁcation was developed in 1994 by an international ad hoc
committee of the American Venous Forum, endorsed by
the Society for Vascular Surgery and incorporated into the
‘Reporting Standards in Venous Disease’ in 1995 (Porter
and Moneta 1995; Kistner et al. 1996). The CEAP classi-
ﬁcation underwent its ﬁrst ofﬁcial review and revision by
an international panel under the auspices of the American
Venous Forum in 2004 by Eklof et al. (2004). Its key
elements are Clinical severity, Etiology or cause, Anatomy
and Pathophysiology.
Clinical severity was the most important criterion for the
initial assessment of index patients in our study. There are
seven grades of increasing clinical severity of CVD: C0, no
evidence for venous disease; C1, superﬁcial spider veins;
C2, simple VV; C3, oedema of venous origin; C4, skin
changes ascribed to venous disease (e.g. pigmentation,
venous eczema and lipodermatosclerosis); C5, skin chan-
ges as deﬁned above, with healed ulceration; C6, skin
changes, as deﬁned above, with active ulceration. Groups
C5 and C6 were combined in our study (‘C5&C6’) because
of the limited number (n = 114) of samples available
(Table 1). Patients of grades C3 to C6 show an increasing
severity of CVI, and all suffer from a functional abnor-
mality of the venous system. For estimating heritability
(Fisher 1918) CVD status (‘affected’, ‘non-affected’),
current age and sex were recorded for all ﬁrst degree rela-
tives. It should be noted that, so far, only a few prevalence
studies have used the CEAP classiﬁcation as a phenotypic
measure (Rabe et al. 2003; Carpentier et al. 2004).
Preoperative diagnostic tests entering into the CEAP
grading of index patients included handheld Doppler
evaluation of the great and small saphenous veins as well
as venous duplex ultrasonography. In combining B mode
imaging with pulsed Doppler, duplex is capable of accu-
rately localizing both the venous obstruction and the val-
vular reﬂux to specify venous segments. Colour duplex
imaging was performed with a Hewlett Packard Image
Point HX, employing a 7.5 MHz probe. Examinations were
undertaken with the patient in a standing position, using the
valsalva manoeuvre and manual calf compression. A reﬂux
[2 s was considered clinically signiﬁcant. For estimating
the actual length of clinically signiﬁcant reﬂux, the hand-
held Doppler and the colour duplex imagine were
Table 1 Data base for the estimation of narrow-sense heritability h
2
CEAP grade No.
pedigrees
No. nuclear
families
No.
individuals
Any (CVD) 2,701 4,033 16,434
C2 (VV) 448 662 2,706
C3 1,698 2,539 10,317
C4 441 656 2,702
C5&C6 114 174 701
C3 to C6 (CVI) 2,253 3,369 13,720
C2 to C4 2,587 3,857 15,725
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123combined with photoplethysmography to gauge the venous
hemodynamics. Repeating the test while ﬁrmly compress-
ing a particular vein allows assessment of the degree of
hemodynamic disturbance contributed by that vein. Spe-
ciﬁcally, if the venous reﬁlling time increases from 10 s
(15) to[25 s when the vein is compressed, this vein can be
assumed to contribute sizeably to the patients health
problem (Meissner 2004).
The genetic contribution to CVD was assessed by esti-
mating the heritability of the disease using a pedigree-
based likelihood approach as implemented in the SOLAR
software package (Almasy and Blangero 1998). A total of
2,701 pedigrees comprising the index patient and the self-
reported disease status of their ﬁrst degree relatives (par-
ents and siblings) were used for analysis. The narrow-sense
heritability, h
2, is deﬁned as the proportion VA of the
phenotypic variance VP in a population that is attributable
to additive genetic causes, i.e., h
2 = VA/VP (Visscher et al.
2008). A 95% conﬁdence interval for h
2 was derived as ±2
standard errors of the estimate. The statistical signiﬁcance
of h
2 was assessed by means of a likelihood ratio test
(Guerra et al. 1999). The inﬂuence of the two main CVD
risk factors, namely sex and age, upon CEAP grade was
estimated using the Kullback–Leibler deviance R
2. The h
2
values of individual CEAP grades or grade ranges
(Tables 1, 2) were estimated grouping index patients into
six subgroups, namely C2, C3, C4, C5&C6, C3 to C6
(CVI) and C2 to C4 (samples without any past or acute
venous ulcer). Sex differences in terms of ascertainment
age, age at CVD onset, disease duration or BMI were
assessed for statistical signiﬁcance using a Welch t test for
unpaired samples. Two-factor analysis of variance was
carried out to evaluate the joint inﬂuence of sex and CEAP
grades on BMI. All statistical analyses were done by using
R version 2.8.1 (http://www.R-project.org).
Results
We recruited 2,701 patients (1,904 females, 797 males),
which represented approximately 90% of the total number
of patients treated at Capio MEC between October 2005
and July 2008 (Table 3). Simple VV (CEAP grade C2) was
diagnosed in 448 (16.6%) of the patients (13.0% of males,
18.1% of females). In total, 2,253 (83.4%) of the index
patients were affected by CVI (CEAP grade C3 to C6), the
majority having either grade C3 (62.8%) or grade C4
(16.3%). Only 4.2% were affected by grades C5 and C6
(Table 3). Males were more severely affected (C4 27.4%,
C5&C6 5.5%) than females (C4 11.7%, C5&C6 3.7%).
Heritability estimation was carried out in 4,033 nuclear
families from 2,701 pedigrees, comprising a total of 16,434
individuals (Table 1), with family sizes varying between 3
and 14 individuals. The h
2 estimate for overall CVD was
17.3 ± 2.5% (P = 1.4 9 10
-13; Table 2). For grade C2
alone, h
2 was 18.5 ± 6.0% (P = 7.3 9 10
-4) whereas h
2
equalled 17.1 ± 2.2% (P = 2.0 9 10
-49) for the CVI
phenotype (grades C3 to C6). The grade-speciﬁc estimates
of h
2 were as follows: 9.2 ± 11.3% for C5&C6 (P = 0.192,
not signiﬁcant), 18.3 ± 2.1% for C3 (P = 1.5 9 10
-9) and
16.7 ± 6.0% for C4 (P = 1.2 9 10
-3). Using age (at blood
donation) and sex as covariates, the Kullback–Leibler
deviance R
2 was estimated to be 10.7% (P = 4.6 9 10
-9).
A notably smaller Kullback–Leibler R
2 was only observed
for C5&C6 grades (3.5%).
The mean ascertainment age of our patients was
56.2 years [standard deviation (SD) 11.1 years, range 18–
83 years; Table 4]. No signiﬁcant age difference was
observed between the two sexes. The overall mean age at
CVD onset was 32.6 years (SD 12.2, range 5–72), with
36.8 years (SD 12.8, range 5–72) for males and 30.8 years
(SD 11.3, range 6–72) for females (Table 4). The grade-
speciﬁc mean age of onset ranged from 30.7 years (SD
10.8) for C5&C6 to 35.8 years (SD 11.6) for C2 whereas
the grade-speciﬁc mean age at ascertainment of our
patients ranged from 52.0 years (SD 12.3) for C2 to
60.9 years (SD 10.4) for C5&C6 (Table 5). The mean
disease duration was 23.4 years (SD 12.9, range 0–63) for
all index patients combined, 19.3 years (SD 12.7, range 0–
55) for males, and 25.1 years (SD 12.9, range 0–63) for
females (Table 4). The grade-speciﬁc mean of the disease
duration ranged from 20.1 years (SD 12.8 years) for grade
Table 2 Estimates of the
narrow-sense heritability (h
2)
for different CEAP grades
a Likelihood ratio test for
h
2 = 0, adjusted for age and sex
CEAP grade h
2 (%) Standard
error (%)
P value
a Kullback–Leibler
Deviance R
2 (%)
Any (CVD) 17.3 2.5 1.4 9 10
-13 10.7
C2 (VV) 18.5 6.0 7.3 9 10
-4 12.2
C3 18.3 2.1 1.5 9 10
-9 11.8
C4 16.7 6.0 1.2 9 10
-3 8.5
C5&C6 9.2 11.3 0.192 3.5
C3 to C6 (CVI) 17.1 2.2 2.0 9 10
-49 10.4
C2 to C4 17.6 2.3 2.2 9 10
-13 11.0
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123C2 to 29.8 years (SD 13.0 years) for grade C5&C6
(Table 5). The mean BMI was 26.8 (SD 4.7, range 14–66)
for all index patients combined, and equalled 27.5 (SD 3.7,
range 20–53) for males and 26.6 (SD 5.0, range 14–66) for
females (Table 4). The grade-speciﬁc BMI ranged from
25.6 (SD 4.5) for C2 to 29.6 (SD 5.2) for C5&C6
(Table 5).
Discussion
The major aim of the present study was to determine the
heritability of CVD and to assess the relative impact of
genetic (familial background, sex) and non-genetic factors
(age, BMI) upon CVD risk. Data from a large number of
individual index patients and the disease status, age and sex
of their ﬁrst degree relatives led us to conclude that the
additive genetic component of CVD is approximately 17%.
Two recently published, population-based studies of
CVD also used the CEAP classiﬁcation to deﬁne the
disease phenotype (Rabe et al. 2003; Carpentier et al.
2004). However, these studies employed a substantially
different recruitment scheme than ours. The Bonn Vein
Study for example, included all CEAP grades thereby
addressing a much lower proportion of severe CVI cases
than we did (Rabe et al. 2003). In line with the Bonn Vein
Study (Rabe et al. 2003), however, males in our study were
found to be more often affected by the severe CEAP grades
C4 to C6 phenotypes than females.
Interestingly, h
2 was found to vary only little with dis-
ease severity (from 18.5% for C2 to 16.7% for C4;
Table 5). Although not formally statistically signiﬁcant
(P = 0.192, Table 2), the substantially lower h
2 estimate
obtained for grades C5&C6 (9.2%) may indicate a smaller
genetic impact upon the severe CVD phenotype, since the
number of samples in this category was comparatively
small (n = 114), however, small h
2 estimate obtained may
also reﬂect higher sampling variance. Therefore, further
studies speciﬁcally targeted at severe grades C5&C6
appear warranted.
Table 3 Prevalence of different
CEAP grades in the study
population
VV varicose veins, CVI chronic
venous insufﬁciency
CEAP grade Total
(n = 2,701)
Males
(n = 797, 29.5%)
Females
(n = 1,904, 70.5%)
C2 (VV) 448 (16.6%) 104 (13%) 344 (18.1%)
C3 1,698 (62.8%) 431 (54.1%) 1,267 (66.5%)
C4 441 (16.3%) 218 (27.4%) 223 (11.7%)
C5&C6 114 (4.2%) 44 (5.5%) 70 (3.7)
C3 to C6 (CVI) 2,253 (83.4%) 693 (87%) 1,560 (81.9)
C2 to C4 2,587 (95.7%) 753 (94.5%) 1,834 (96.3%)
Table 4 Characteristics of CVD patients
All patients
(n = 2,701)
SD
(range)
Males
(n = 797)
SD
(range)
Females
(n = 1,904)
SD
(range)
P value
Age at
ascertainment
56.2 years 11.1 years (18–83) 56.2 years 11.6 years (18–81) 56.1 years 11.9 years (21–83) 0.95
(not signiﬁcant)
Age at onset 32.6 years 12.2 years (5–72) 36.8 years 12.8 years (6–72) 30.8 years 11.3 years (5–72) 2.2 9 10
-16
Disease age 23.4 12.9 years (0–63) 19.3 years 12.7 years (0–55) 25.1 years 12.9 years (0–63) 2.2 9 10
-16
BMI 26.8 4.7 (14–66) 27.5 3.7 (20–53) 26.6 5.0 (14–66) 9.2 9 10
-7
Given are the overall and sex-speciﬁc means, standard deviations (SD) and ranges
Table 5 CEAP grade-speciﬁc characteristics of CVD patients
CEAP grade Age at onset Age at ascertainment Disease age BMI
C2 (VV) 35.8 (11.6, 5–72) 52.0 (12.3, 18–82) 20.1 (12.8, 0–54) 25.6 (4.5, 20–42)
C3 32.9 (12.1, 6–72) 56.4 (10.6, 23–82) 23.4 (12.6, 0–63) 26.5 (4.5, 14–66)
C4 33.2 (12.7, 10–72) 58.3 (10.5, 24–81) 25.3 (13.0, 1–56) 28.3 (4.8, 18–46)
C5&C6 30.7 (10.8, 14–71) 60.9 (10.4, 33–83) 29.8 (13.0, 6–61) 29.6 (5.2, 21–45)
C3 to C6 (CVI) 32.8 (12, 6–72) 57 (10.6, 23–83) 24.1 (12.8, 0–63) 27.1 (4.7, 14–66)
C2 to C4 32.8 (12.1, 5–72) 55.9 (11.1, 18–82) 23.2 (12.8, 0–63) 26.7 (4.6, 14–66)
Given are the means and, in brackets, standard deviations and ranges
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123The main CVD risk factors identiﬁed so far have been
age (at ascertainment), female sex and familial history
(Rabe et al. 2003), and our study was the ﬁrst to include
age at disease onset and the disease duration disease as
well. Index patients with simple VV (C2) were ascertained
at a mean age of 52 years whereas those with a more severe
form of CVI were ascertained at a mean age of 60.9 years.
These results corroborate an earlier multicenter study by
Carpentier (2004), which also revealed a statistically sig-
niﬁcant association between a higher CEAP grade and an
older current age of patients. However, an inverse rela-
tionship was observed in our study between disease
severity and the age at disease onset. Patients affected by
simple VV (C2) were ﬁrst affected at 35.8 years compared
to 30.7 years for patients with CVI (C3 to C5&C6). This
discrepancy may be explicable in terms of the CVI phe-
notype requiring a longer time period for its etiopathology
than VV. Indeed, CVD is a progressive disease where those
with longer disease duration (i.e., earlier onset and/or older
current age) can be expected to show the worst phenotype.
Consequently, a remarkable increase in disease duration
with disease severity was observed in our study, ranging
from 20.1 years for C2, via 23.4 years and 25.3 years for
C3 and C4, respectively, to 29.8 years for C5&C6.
In most studies undertaken so far, CVD has been found
to be more prevalent among women than among men
(Rabe et al. 2003), although this difference was only small
in a recent study by Labropoulos (2003). Among our
samples, twice as many patients were female (n = 1,904,
70.5%) than male (n = 797, 29.5%) thereby highlighting
the CVD-predisposing role of the female sex (Table 3).
The reasons for the observed sex difference may be mani-
fold. Clearly, women are more likely to seek medical
attention for varicose veins and are about three times more
likely to undergo treatment (Madar et al. 1986). However,
a remarkable sex difference was also observed in our data
in terms of the mean age at disease onset, with females
showing ﬁrst symptoms of CVD at 30.8 years of age,
compared to 36.8 years for males (Table 4), and in terms
of disease duration (19.3 years for males, 25.1 years for
females). The higher proportion of female CVD patients
consistently noted in previous reports, may thus be at least
partially explicable by a different timing of disease in the
two sexes.
Obesity has been noted to be an additional risk factor for
CVD (De Backer 1997; Fowkes et al. 1999). Indeed, the
mean BMI of the index patients in our study was 26.8
(Table 4). Many studies considered BMI to be more
important in females than in males (De Backer 1997;
Fowkes et al. 1999). In our study, however, only a small
yet signiﬁcant difference (P = 9.2910
-7) difference was
observed between the mean BMI of males (27.5, SD 3.7)
and females (26.6, SD 5.0; Table 4). However, obesity
seems to play a more important role for the development of
severe forms of CVD (26.5 for C3, via 28.3 for C4, to 29.6
for C5&C6; Table 5). Indeed, in a two-factor analysis of
variance, sex and CEAP grade both had a signiﬁcant effect
upon BMI (P = 7.8910
-6 and P = 2.2910
-16).
Two major strengths of our study have been (1) the use
of a high-risk population, thereby resulting in a higher
prevalence of both simple VV and CVI than, for example,
the Bonn Vein Study (Rabe et al. 2003), and (2) a large
number of nuclear families available for heritability ana-
lysis. Unfortunately, all data other than those on index
patients were self-reported. However, we do not regard this
as a major source of upward bias for our heritability esti-
mates because, if anything, a less than perfect patient recall
will have introduced additional variance into the analysis,
thereby leading to an underestimate of the true level of
familiarity of CVD. Another possible drawback may have
been that, by deﬁnition, h
2 is population-dependent, i.e. h
2,
estimates from one population do not necessarily reﬂect
the heritability of the same trait in another population
(Visscher et al. 2008). Therefore, future studies are required
to clarify whether our heritability estimate is indeed repre-
sentative of CVD in general. These limitations notwith-
standing, our results strongly encourage efforts to identify
susceptibility genes predisposing for severe forms of CVD.
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